Trial · NCT02668146
An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor
NCT02668146, Phase 2, Unknown, VA Greater Los Angeles Healthcare System
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor. Trials, record NCT02668146. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02668146
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor
- NCT number
- NCT02668146
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 16 participants, actual
- Lead sponsor
- VA Greater Los Angeles Healthcare System
- Conditions
- Essential Tremor
- Interventions
- Perampanel, Placebo
- First posted
- 2016-01-29
- Last updated
- 2016-09-12
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Tremor reduction. TETRAS scale, performance sub scale. | 40 weeks | This scale evaluates tremor of various body parts during postures, movement and tasks. Items are scored from 0 to 4, with 4 representing highest severity. Maximum score is 64. |
| Primary | Tremor reduction. TETRAS scale. Activity of Daily Living subscale. | 40 weeks | The subject rates to what extent tremor affects activities in a 12-item, 0-to-4 scale. Maximum score is 48. |
| Primary | Tremor reduction. TETRAS scale. Subject Global Impression of Change. | 40 weeks | Subjects rate the degree of change from minus 3 to plus 3. |
| Primary | Tremor reduction. TETRAS scale. QUEST subscale (QUality of life in Essential Tremor). | 40 weeks | 30-item questionnaire in which the subject rates on a 0 to 4 scale how much tremor affects aspects of life. |
| Primary | Safety. vitals; | 40 weeks | Weight (lbs), respiration rate (rps), heart rate (bps) and blood pressure (mmhg). |
| Primary | Tolerability. Adverse Events. | 40 weeks | At each clinic and phone visit, the PI and coordinator will collect information on any adverse events. An Adverse Event will be defined as any clinically undesirable event. |
| Primary | Safety; laboratory testing | 40 weeks | At each clinic visit. Laboratory testing will be done. This will include metabolic panel (serum electrolytes, glucose (mg/dl) , creatinine (mg/dl) , calcium (mg/dl), magnesium (mg/dl), Complete Blood Count(CBC) (mg/dl), White Blood Count (WBC) (k/ul), platelets (k/ul), hepatic panel (total BILIRUBIN, Total PROTEIN, ALKALINE PHOSPHATASE, ALANINE AMINOTRANSFERASE, ASPARTATE AMINOTRANSFERASE, ALBUMIN GLUTAMYL TRANSFERASE LDH), and urinalysis. |
| Primary | Safety. Laboratory testing; screen visit testing | screen visit | Screen Visit testing will include hemoglobin A1c (%), free thyroxin (ng/dl), and Thyroid Stimulating Hormone (TSH) (uIU/mL) . An EKG will be performed. |
| Secondary | Treatment effects on Daily Living (The QUEST scale to assess quality of life) | 40 weeks | Assess the effect of treatment on tremor-affected activities of daily living. The QUEST scale to assess quality of life in essential tremor. It is a 30-item questionnaire in which the subject rates on a 0 to 4 scale how much tremor affects aspects of life |
| Secondary | QOLIE changes | 40 weeks | Assess changes in Quality Of Life (QOLIE). |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02668146
GET https://conductscience.org/api/trials/v1/NCT02668146/registered